Published in Women's Health Weekly, October 31st, 2002
The multicenter, double-blind, randomized, placebo-controlled, phase II trial will determine the effect of two AGIX-4207 dosing regimens on established biomarkers of RA, including erythrocyte sedimentation rate (ESR) and highly...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.